Back to Search Start Over

Natural course of pain in chronic pancreatitis is independent of disease duration.

Authors :
Vipperla K
Kanakis A
Slivka A
Althouse AD
Brand RE
Phillips AE
Chennat J
Papachristou GI
Lee KK
Zureikat AH
Whitcomb DC
Yadav D
Source :
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] [Pancreatology] 2021 Apr; Vol. 21 (3), pp. 649-657. Date of Electronic Publication: 2021 Feb 02.
Publication Year :
2021

Abstract

Objectives: Pain burn-out during the course of chronic pancreatitis (CP), proposed in the 1980s, remains controversial, and has clinical implications. We aimed to describe the natural course of pain in a well-characterized cohort.<br />Methods: We constructed the clinical course of 279 C P patients enrolled from 2000 to 2014 in the North American Pancreatitis Studies from UPMC by retrospectively reviewing their medical records (median observation period, 12.4 years). We assessed abdominal pain at different time points, characterized pain pattern (Type A [short-lived pain episodes] or B [persistent pain and/or clusters of recurrent severe pain]) and recorded information on relevant covariates.<br />Results: Pain at any time, at the end of follow-up, Type A pain pattern or B pain pattern was reported by 89.6%, 46.6%, 34% and 66% patients, respectively. In multivariable analyses, disease duration (time from first diagnosis of pancreatitis to end of observation) did not associate with pain - at last clinical contact (OR, 1.0, 95% CI 0.96-1.03), at NAPS2 enrollment (OR 1.02, 95% CI 0.96-1.07) or Type B pain pattern (OR 1.01, 95% CI 0.97-1.04). Patients needing endoscopic or surgical therapy (97.8 vs. 75.2%, p < 0.001) and those with alcohol etiology (94.7 vs. 84.9%, p = 0.007) had a higher prevalence of pain. In multivariable analyses, invasive therapy associated with Type B pain and pain at last clinical contact.<br />Conclusions: Only a subset of CP patients achieve durable pain relief. There is urgent need to develop new strategies to evaluate and manage pain, and to identify predictors of response to pain therapies for CP.<br />Competing Interests: Declaration of competing interest DCW serves as a consultant for AbbVie, Regeneron, Ariel Precision Medicine, is a cofounder of Ariel Precision Medicine and may have equity. Other authors report no conflict.<br /> (Copyright © 2021. Published by Elsevier B.V.)

Details

Language :
English
ISSN :
1424-3911
Volume :
21
Issue :
3
Database :
MEDLINE
Journal :
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Publication Type :
Academic Journal
Accession number :
33674197
Full Text :
https://doi.org/10.1016/j.pan.2021.01.020